Summary
ALCON'S independent directors have criticised a takeover bid from Novartis, saying the Swiss drugmaker is trying to circumvent protections for minority shareholders.
Novartis aims to buy the rest of eyecare group Alcon for dollars 39.3 billion to reduce its reliance on prescription drugs, but is offering minority shareholders a worse deal than 52 per cent owner Nestle.See the full content of this document
Extract
In Brief: Eyecare Firm Sees No Good in Takeover Bid
The Ba...
See the full content of this document
Sponsored links
